The estimated Net Worth of Funds Management Lp Anson A... is at least $2.61 Million dollars as of 22 September 2023. Funds A owns over 48,060 units of MEI Pharma Inc stock worth over $2,609,848 and over the last few years Funds sold MEIP stock worth over $0.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Funds A MEIP stock SEC Form 4 insiders trading
Funds has made over 2 trades of the MEI Pharma Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Funds bought 48,060 units of MEIP stock worth $329,211 on 22 September 2023.
The largest trade Funds's ever made was buying 153,600 units of MEI Pharma Inc stock on 20 September 2023 worth over $938,496. On average, Funds trades about 50,415 units every 1 days since 2023. As of 22 September 2023 Funds still owns at least 864,188 units of MEI Pharma Inc stock.
You can see the complete history of Funds A stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at MEI Pharma Inc
Over the last 12 years, insiders at MEI Pharma Inc have traded over $26,282,680 worth of MEI Pharma Inc stock and bought 597,450 units worth $2,541,200 . The most active insiders traders include Ventures Vii, Llc Vivo Vent..., Leaf Ventures Ii, L.P.New L..., and Josiah T Austin. On average, MEI Pharma Inc executives and independent directors trade stock every 91 days with the average trade being worth of $360,383. The most recent stock trade was executed by Funds Management Lp Anson A... on 22 September 2023, trading 48,060 units of MEIP stock currently worth $329,211.
What does MEI Pharma Inc do?
mei pharma (nasdaq: meip) is a san diego-based oncology company focused on the clinical development of novel therapies for cancer. our lead drug candidate is pracinostat, a potential best-in-class, oral hdac inhibitor that has been granted breakthrough therapy designation from the fda in combination with azacitidine for the treatment of patients with newly diagnosed aml who are ≥75 years of age or unfit for intensive chemotherapy. our pipeline of drug candidates also includes me-401 (formerly pwt143), a next-generation oral pi3k delta inhibitor, and me-344, a novel mitochondrial inhibitor. for more, please go to www.meipharma.com.
What does MEI Pharma Inc's logo look like?
Complete history of Funds A stock trades at MEI Pharma Inc
MEI Pharma Inc executives and stock owners
MEI Pharma Inc executives and other stock owners filed with the SEC include:
-
Daniel Gold,
President, Chief Executive Officer, Director -
David Urso,
Chief Operating Officer, General Counsel -
Dr. Daniel P. Gold,
Pres, CEO & Director -
Brian Drazba,
Chief Financial Officer, Secretary -
David M. Urso B.A., Esq., J.D.,
COO & Gen. Counsel -
Robert Mass,
Chief Medical Officer -
Brian G. Drazba B.A., CPA, CPA,
CFO & Sec. -
Dr. Richard G. Ghalie,
Chief Medical Officer -
Dr. Robert D. Mass,
Strategic Advisor -
Charles Baltic,
Independent Director -
Nicholas Glover,
Independent Director -
Kevan Clemens,
Independent Director -
Frederick Driscoll,
Independent Director -
Tamar Howson,
Independent Director -
Cheryl Cohen,
Director -
Brian Powl,
Senior Vice President of Marketing -
Tina Clark Beamon Esq., J.D.,
Chief Compliance Officer -
Dr. Karen E. Potts Ph.D.,
Sr. VP of Regulatory Affairs -
Dr. Ofir Moreno,
Sr. VP of Pharmaceutical Sciences -
Jamie A. Tereschuck,
VP of HR -
David A. Walsey J.D., L.L.M.,
VP of IR & Corp. Communications -
Leaf Ventures Ii, L.P.New L...,
-
Ventures V, Llc Vivo,
-
Leah Rush Cann,
Director -
Thomas M. Zech,
Chief Financial Officer -
William Dodge Rueckert,
Director -
Ventures Vii, Llc Vivo,
-
Christine Anna White,
Director -
Ventures V, Llc Vivo Ventur...,
-
Leaf Ventures Ii, L.P.New L...,
-
Leaf Ventures Ii, L.P.New L...,
-
Ventures Vii, Llc Vivo Vent...,
-
Josiah T El Coronado Holdin...,
-
Leaf Ventures Ii, L.P.New L...,
-
Josiah T Austin,
10% owner -
Bryan Williams,
Director -
Ltd Novogen,
10% owner -
Sujay Kango,
-
Richard G Ghalie,
Chief Medical Officer -
Thomas C Reynolds,
-
Funds Management Lp Anson A...,
-
Funds, Lp Cable Car Capital...,
-
Steven D Wood,
-
James P Flynn,